Corautus Genetics to Present at the Roth Capital Partners New York Conference

Corautus Genetics to Present at the Roth Capital Partners New
York Conference
Presentation to be Webcast Live September 15, 2004 at 8:30 A.M. EDT 


ATLANTA, Sept. 9  /PRNewswire-FirstCall/ -- Richard E. Otto, President and CEO
of Corautus Genetics Inc. (AMEX:CAQ), is scheduled to make a presentation at
the Roth Capital Partners New York Conference on Wednesday, September 15, 2004
at 8:30 a.m. (EDT).  The conference will be held at the St. Regis Hotel in New
York, NY on September 13-15, 2004.

Mr. Otto will discuss Corautus' recently initiated GENASIS Phase IIb clinical
trial for severe cardiovascular disease, present the Company's broadly enabling
technology platform, and review additional development activities and the
Company's overall business strategy.

A live webcast of the presentation can be accessed by logging onto
http://www.wsw.com/webcast/roth4/caq , and a replay will be available for 60
days following the conference.

About the Roth Capital Partners New York Conference

This annual event is the largest in the nation for emerging growth companies.
It provides a concentrated forum where institutional investors can meet the
executives of growth companies hand picked by Roth Capital's research team. The
conference will highlight approximately 225 companies from industry groups
including Health Care/Life Sciences; Consumer Products; Defense & Industrial
Technologies; Digital Media, IT & Entertainment; Broadband & Fiber Optics;
Gaming; and Business and Banking/Financial Services. For more information about
the conference visit:
http://www.rothcp.com/Conf%20NY%20Web%20Site/Roth.htm?content=home

About Corautus Genetics

Corautus Genetics Inc. is a clinical stage biopharmaceutical company dedicated
to the development of gene transfer therapy products for the treatment of
severe cardiovascular and peripheral vascular disease.  Corautus is currently
developing a gene transfer product using the Vascular Endothelial Growth
Factor-2 (VEGF-2) gene to promote therapeutic angiogenesis in ischemic muscle. 
In July 2003, Corautus entered into a series of agreements with Boston
Scientific Corporation to fund, develop, commercialize and distribute the
VEGF-2 gene therapy products.

Forward-Looking Statement

This press release may contain forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Such statements are subject to certain factors, risks and uncertainties that
may cause actual results, events and performances to differ materially from
those referred to in such statements. These risks include statements which
address operating performance, events or developments that we expect or
anticipate will occur in the future, such as projections about our future
results of operations or our financial condition, benefits from the alliance
with Boston Scientific, research, development and commercialization of our
product candidates, and in particular whether early-stage clinical trial
results are any indication of results in subsequent clinical trials,
anticipated trends in our business, manufacture of sufficient and acceptable
quantities of our proposed products, approval of our product candidates,
meeting additional capital requirements, and other risks that could cause
actual results to differ materially. These risks are discussed in Corautus
Genetics Inc.'s Securities and Exchange Commission filings, including, but not
limited to, the risk factors in Corautus' Annual Report on Form 10-K for the
year ended December 31, 2003 (File No. 001-15833) filed March 30, 2004, which
are incorporated by reference into this press release.

Investor Relations, Jack W. Callicutt of Corautus Genetics Inc.,
[phone], or fax, [phone]; and Media Relations, Justin Jackson
of Burns McClellan, on behalf of Corautus Genetics, [phone] 

DATASOURCE: Corautus Genetics Inc.



CONTACT:  Investor Relations, Jack W. Callicutt of Corautus Genetics

Inc., [phone], or fax, [phone]; or Media Relations, Justin

Jackson of Burns McClellan, [phone], for Corautus Genetics Inc.



Web site:  http://www.corautus.com/

http://www.wsw.com/webcast/roth4/caq 

Copyright